ImmunityBio Inc. Stock
Price
Target price
€7.02
€7.02
-0.920%
-0.066
-0.920%
€10.00
17.05.24 / Tradegate
WKN: A2QQ2E / Name: ImmunityBio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
ImmunityBio Inc. Stock
The price for the ImmunityBio Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.066 (-0.920%).
Currently there is a rather positive sentiment for ImmunityBio Inc. with 3 Buy predictions and 0 Sell predictions.
With a target price of 10 € there is a positive potential of 42.37% for ImmunityBio Inc. compared to the current price of 7.02 €.
So far the community has only identified positive things for ImmunityBio Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ImmunityBio Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
ImmunityBio Inc. | -0.920% | -6.645% | 42.619% | 135.705% | 48.814% | -48.512% | - |
Ardelyx Inc. | 0.340% | -0.416% | 16.992% | 98.564% | 24.360% | 28.357% | - |
Evolus Inc | 5.130% | 4.237% | 11.818% | 41.379% | 35.912% | 70.833% | - |
Salarius Pharmaceuticals Inc. | 7.850% | -5.069% | -4.630% | -67.040% | -25.766% | -98.502% | -99.992% |
Comments
News
5 Stocks with Unusually Large Short Interest
With the broader market reaching new all-time highs, primarily driven by the tech sector and specifically semiconductor stocks fueled by the hype surrounding AI, the spotlight is once again